Dyne Therapeutics, Inc. 4

Jason P. Rhodes received an option award for 35,152 shares of Dyne Therapeutics, Inc. common stock at a $17.04 exercise price.

On June 5, 2026, Jason P. Rhodes received a grant of stock options to purchase 35,152 shares of Dyne Therapeutics, Inc. common stock at an exercise price of $17.04 per share, with the options vesting in full on the earlier of June 5, 2027 or the company’s 2027 annual meeting of stockholders, subject to continued service. The grant is recorded as a derivative security (stock option) with no immediate cash outlay, and upon full vesting and exercise would convert into 35,152 shares of common stock. Rhodes is obligated to transfer the economic benefit from any sale of the underlying shares to Atlas Venture Life Science Advisors, LLC, and therefore disclaims beneficial ownership except for any pecuniary interest. Following this award, his reported derivative holdings related to this grant total 35,152 option-linked shares.

Filing Facts

CIK

1818794

Ticker

DYN

Form

4

Source Type

sec

Accession

0001193125-26-264022

Alert Tier

5